Wedbush Assumes Coverage on Achillion Pharmaceuticals (ACHN) at Outperform; Optimism from Pipeline
Tweet
Share
E-mailGet Alerts ACHN Hot Sheet
Price: $0.79 --0%
Rating Summary:
11 Buy, 7 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Rating Summary:
11 Buy, 7 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Join SI Premium – FREE
Wedbush assumes coverage on Achillion Pharmaceuticals (NASDAQ: ACHN) with a Outperform. PT $13.00.
Analyst, Akiva Felt, said, "...the company continues to make progress developing its internal pipeline of Hepatitis C drug candidates. Meanwhile, ACHN may also benefit from renewed interest in DAAs outside the nucleotide class of drugs, particulrly if upcoming data from Gilead’s (Nasdaq: GILD)(Not Rated) GS-7977 in genotype-1 (GT1) treatment-naïve patients leaves room for improvement."
"Our optimism for ACHN reflects a rising likelihood that non-nuc DAAs will be a significant part of all-oral HCV treatments. In light of the company’s potential to capitalize on the multi-billion market for HCV therapy."
For an analyst ratings summary and ratings history on Achillion Pharmaceuticals click here. For more ratings news on Achillion Pharmaceuticals click here.
Shares of Achillion Pharmaceuticals closed at $10.22 yesterday.
Analyst, Akiva Felt, said, "...the company continues to make progress developing its internal pipeline of Hepatitis C drug candidates. Meanwhile, ACHN may also benefit from renewed interest in DAAs outside the nucleotide class of drugs, particulrly if upcoming data from Gilead’s (Nasdaq: GILD)(Not Rated) GS-7977 in genotype-1 (GT1) treatment-naïve patients leaves room for improvement."
"Our optimism for ACHN reflects a rising likelihood that non-nuc DAAs will be a significant part of all-oral HCV treatments. In light of the company’s potential to capitalize on the multi-billion market for HCV therapy."
For an analyst ratings summary and ratings history on Achillion Pharmaceuticals click here. For more ratings news on Achillion Pharmaceuticals click here.
Shares of Achillion Pharmaceuticals closed at $10.22 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Starts Kanzhun Ltd. (BZ) at Neutral
- Jefferies Assumes Honeywell International (HON) at Hold
- Chardan Starts Odysight.AI Inc. (ODYS) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
